GBP1 has been shown to promote proliferation, migration, and metastasis in lung cancer by binding to indoleamine 2,3-dioxygenase 1 (IDO1) and to enhance resistance to epidermal growth factor receptor (EGFR) inhibitors by interacting with phosphoglycerate kinase 1 (PGK1) [10,11]. Here, IDO1 is linked to lung cancer.